Biora Therapeutics presented data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist Delivered through the BioJet Biotherapeutic Delivery Platform in Swine” at the 59th annual meeting of the European Association for the Study of Diabetes, in Hamburg, Germany. “The category-leading bioavailability results for our autonomous, next-gen BioJet device, along with its ability to deliver existing liquid formulations at multi-milligram doses similar to injection, have enabled us to accelerate testing with our collaborators’ molecules,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “We are seeing increased interest in our platform and continue to advance our stated goal to progress our collaborations and rapidly work towards meaningful partnerships,” continued Mohanty.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIOR:
- Biora Therapeutics price target lowered to $50 from $65 at H.C. Wainwright
- Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
- Biora Therapeutics submits IND application to FDA for BT-600 program
- Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
- Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference